Peptora
← All peptides

Cagrilintide

★ 75

Cagrilintide (long-acting amylin analog)

Long-acting amylin analog — appetite control via different pathway than GLP-1

Fat Loss
Half-life
~7 days (acyl-modified for once-weekly dosing)
Route
SubQ
Cycle
Long-term maintenance like
Status
Phase 3 monotherapy trials (Novo Nordisk). Expected to file FDA submission 2025-2026 as alternative or addition to semaglutide.

About

Novo Nordisk's long-acting amylin analog. Slows gastric emptying and suppresses appetite via amylin receptors. Studied as monotherapy and as the cagri component of CagriSema.

Mechanism

Selective amylin receptor (AMY1-3) agonist; pancreatic amylin co-secreted with insulin. Slows gastric emptying, suppresses post-meal glucagon, reduces appetite via hindbrain area postrema.

Dosage

beginner

Amount
0.3 mg
Frequency
1x per week
Route
Subcutaneous (SubQ)
Duration
Titration phase 4 weeks

standard

Amount
0.6 → 1.2 → 1.7 mg
Frequency
1x per week, increasing every 4 weeks
Route
SubQ
Duration
16-20 weeks

advanced

Amount
2.4 mg (max)
Frequency
1x per week
Route
SubQ
Duration
Long-term
Timing

Same day each week. Independent of meals.

Cycle structure

Long-term maintenance like GLP-1 drugs. Taper down if discontinuing to avoid rebound appetite.

Reconstitution & Storage

5 mg + 1 mL → 5 mg/mL

Compounded version. Clinical product is pre-filled pen.

Dosing reference — units to draw

Concentration = peptide mass ÷ bacteriostatic water; units to draw = dose volume (mL) × 100 on a U-100 insulin syringe. Each vial size below is shown at 1 mL, with the units to draw for a typical 0.3–4.5 mg dose.

Cagrilintide reconstitution: vial size, bacteriostatic water, resulting concentration, and units to draw on a U-100 insulin syringe for a typical dose.
Vial BAC water Concentration Units to draw
5 mg 1 mL 5 mg/mL 6–90 units
10 mg 1 mL 10 mg/mL 3–45 units

Open Cagrilintide in the reconstitution calculator →

Lyophilized: refrigerated 2-8°C. After reconstitution: 2-8°C, 28 days.

Benefits

  • • 10-12% weight loss as monotherapy in Phase 2
  • • Different mechanism than GLP-1 (complementary or alternative)
  • • Less nausea than semaglutide
  • • Smooth appetite control without 'food noise' crashes
  • • Pairs synergistically with semaglutide (see CagriSema)

Side effects

  • • Nausea (mild, less than GLP-1)
  • • Decreased appetite (intended)
  • • Injection-site reactions
  • • Hypoglycemia (if combined with other diabetes meds)

Contraindications

  • • Pregnancy and breastfeeding
  • • Severe gastroparesis
  • • Personal history of pancreatitis
  • • Type 1 diabetes (limited data)

Gender notes

Men

Same dose. Studied in mixed-sex Phase 2/3 cohorts.

Women

Same dose. Check fertility plans — limited human data.

Research

Stacks well with

SEMAGLUTIDE TESAMORELIN MOTS-C

Cagrilintide FAQ

How do you reconstitute Cagrilintide?

Add 1 mL of bacteriostatic water to a 5 mg vial of Cagrilintide, which gives a concentration of 5 mg/mL. Inject the water slowly down the vial wall and swirl gently — never shake.

What is a typical Cagrilintide dose?

A typical research dose of Cagrilintide is 0.3–4.5 mg, 1x per week, increasing every 4 weeks. This is educational information, not medical advice.

How many units of Cagrilintide do I draw?

From a 5 mg vial reconstituted with 1 mL of bacteriostatic water, draw 6–90 units on a U-100 insulin syringe for a 0.3–4.5 mg dose.

Track Cagrilintide doses in the app

Built-in reconstitution calculator, dose log, and reminders. Free on Android.

Get on Google Play

Educational use only. Not medical advice. Many peptides shown are not FDA-approved and remain research compounds. Always consult a qualified healthcare provider.